Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia Total potential deal value of $110 million plus royaltiesKiora to receive an immediate $1.25 million exclusive option feeIf the option...

Kiora Pharmaceuticals just announced a $110M licensing deal with Japan-based Senju Pharmaceutical to develop and commercialize KIO-301, their optogenetics-based vision restoration program, across Asia.

www.newsfilecorp.com/release/2542...

#VisionResearch #RetinalDiseases #KIO301 #CureCHM